Sunday, October 08, 2017 11:27:42 PM
This seems to be a good potential for a stock to go long - but I have some questions..Hopefully someone can shed some light.
1. From recent news, the company indicated that the recent stock issuance is to allow the Company to fund the "initiation of its Phase 3 clinical program" of RP-G28 for the treatment of lactose intolerance, expected to begin in the first half of 2018. --->The word "initiation" somehow really bothers me as it sounds like, there may be more coming. Can someone shed somelight on this?
2. Potential of >$1.2Billions of prescription market. Can someone translate tha to sales or perhaps potential sp?
3. Timeline of completion of P3 Trial?
Thanks
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM